Report

Introduction

This report and dataset inventory identifies individual-level measures for conducting patient-centered outcomes research (PCOR) relevant to adults with disabilities, aged 18–64 years.

Pathogens that have evolved to be resistant to the drugs currently used to treat infections are an ongoing threat to public health, animal health, food production, and national security. Globally, a recent analysis estimated that 1.2 million deaths were caused by antibiotic-resistant (AR) bacteria in 2019, making this threat a leading cause of death for people of all ages worldwide.

This research report updates prior reports on Medicare FFS telehealth trends during the COVID-19 public health emergency with data through end of 2021, by beneficiary characteristics, visit specialty and geography including by state. Medicare telehealth flexibilities during the COVID-19 pandemic continued to encourage use of telehealth among Medicare beneficiaries in 2021.

ASPE contracted with RAND Health Care to catalogue and assess state changes to Medicaid telehealth policies during the COVID-19 PHE through May 2022 and identify the driving circumstances, motivations, and evidence supporting telehealth policy decisions during the COVID-19 Public Health Emergency (PHE).

This first report focuses largely on establishing a baseline and a framework for further evaluation.

The Inflation Reduction Act (IRA) will make key changes to improve drug affordability for people who have Medicare.

Researchers from ASPE, NORC, Washington University in St. Louis, Catholic Physicians’ Guild of San Antonio, and the U.S.

This report summarizes the results of the evaluation conducted on different PPRL packages to identify the best fit for CODI. Included in the evaluation are the open source anonlink and the R PPRL package, as well as a commercial product called CURL (Colorado University Record Linkage), developed by the University of Colorado.

The goal of this project was to strengthen the coordinated registry network as a real-world data source for high quality, relevant, reliable, timely and actionable evidence to improve patient outcomes of medical devices, specifically for technologies affecting women’s health.